Work

Abstract CT120: The randomized phase 1/2 LITESPARK-024 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma (RCC)

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2023-ct120

Authors: David F. McDermott, Avivit Peer, Neeraj Agarwal, Michael B. Atkins, Jerry Cornell, Rodolfo F. Perini, Kenneth F. Grossmann, Howard Gurney

Institutions: Beth Israel Deaconess Medical Center, Rambam Health Care Campus, Huntsman Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Westmead Hospital, Macquarie University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4365513284

Cites:

Cited by:

Related to: 10